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In vivo dual-delivery of glucagon like peptide-1
(GLP-1) and dipeptidyl peptidase-4 (DPP4)
inhibitor through composites prepared by
microfluidics for diabetes therapy
F. Araújo,a,b,c,d N. Shrestha,d M. J. Gomes,a,b,c B. Herranz-Blanco,d D. Liu,d
J. J. Hirvonen,d P. L. Granja,a,b,c H. A. Santosd and B. Sarmento*a,b,e
Oral delivery of proteins is still a challenge in the pharmaceutical field. Nanoparticles are among the most
promising carrier systems for the oral delivery of proteins by increasing their oral bioavailability. However,
most of the existent data regarding nanosystems for oral protein delivery is from in vitro studies, lacking
in vivo experiments to evaluate the efficacy of these systems. Herein, a multifunctional composite system,
tailored by droplet microfluidics, was used for dual delivery of glucagon like peptide-1 (GLP-1) and dipep-
tidyl peptidase-4 inhibitor (iDPP4) in vivo. Oral delivery of GLP-1 with nano- or micro-systems has been
studied before, but the simultaneous nanodelivery of GLP-1 with iDPP4 is a novel strategy presented here.
The type 2 diabetes mellitus (T2DM) rat model, induced through the combined administration of
streptozotocin and nicotinamide, a non-obese model of T2DM, was used. The combination of both drugs
resulted in an increase in the hypoglycemic effects in a sustained, but prolonged manner, where the
iDPP4 improved the therapeutic efficacy of GLP-1. Four hours after the oral administration of the system,
blood glucose levels were decreased by 44%, and were constant for another 4 h, representing half of the
glucose area under the curve when compared to the control. An enhancement of the plasmatic insulin
levels was also observed 6 h after the oral administration of the dual-drug composite system and,
although no statistically significant differences existed, the amount of pancreatic insulin was also higher.
These are promising results for the oral delivery of GLP-1 to be pursued further in a chronic diabetic
model study.
Introduction
The development of therapeutic proteins has increased expo-
nentially over the past few decades.1 Owing to their natural
origin, proteins and peptides have exquisite effectiveness,
activity, specificity and relatively lower toxicity, which has a sig-
nificant impact in the treatment of numerous diseases.2
However, due to their delicate structure, they must be admini-
strated through parenteral routes. The use of proteins as thera-
peutic agents for oral delivery is still underachieved, which
keeps the desired oral administration of proteins yet in its
infancy.3,4
With the expanding knowledge in nanomedicine the devel-
opment of nanosized delivery systems is revolutionizing the
pharmaceutical field, by considerably improving the thera-
peutic effects of most of the drugs and their bioavailability.
Nanoparticles are also regarded as promising nanocarriers for
oral protein delivery.5,6 These nanoparticles are formed by bio-
materials that can be tailored towards the desired administration
route and can further be associated with other molecules in
order to improve their interaction with the target organ.7
Nevertheless, despite the huge efforts in the development of
nanoparticles, most of the existent data essentially addresses
in vitro studies, lacking in vivo experiments to evaluate the
efficacy of the developed nanosystems.
Herein, an innovative approach for type 2 diabetes mellitus
(T2DM) therapy is proposed. Within the multifunctional tailor-
able composite system for dual-drug delivery previously
described,8 glucagon-like peptide-1 (GLP-1) and a dipeptidyl
peptidase-4 (DPP4) inhibitor (iDPP4) drug were combined in a
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single system, aiming to overcome the side effects associated
with each one of them separately. Due to its incretin effect
(insulin secretion after a meal, in a glucose-dependent
manner) GLP-1 is one of the most promising therapeutic mole-
cules for T2DM therapy, avoiding the well-known hypoglycemic
effects of current drugs.9,10 Nevertheless, GLP-1 has a very
short half-life, being cleaved by the DPP4 enzyme in less than
2 minutes.11 This system was assembled through the droplet
microfluidics technique8 and it is based on the use of poly-
meric poly(lactic-co-glycolic acid) (PLGA) nanoparticles. These
nanoparticles were claimed as adequate candidates to provide
a protective, stable and biocompatible environment to the
encapsulated peptides and proteins.2,12,13 The nanoparticles
were functionalized with chitosan (CS) and a cell-penetrating
peptide (CPP) and, as previously described by our group,
showed high and strong interactions with intestinal cells
in vitro.8,14 CS is a positively charged polymer used to a large
extent due to its advantageous characteristics of adhesion to
negatively charged mucosae and cell membranes, thereby
increasing cell permeability of intestinal cells by transiently
opening tight junctions and affecting the paracellular and
intracellular pathways, without changing the junctional mor-
phology or causing any damage to the cells.15,16 In turn, CPP
has the ability to cross the cellular membranes without
causing a cellular response, increasing the transcellular trans-
port.17,18 We have previously shown in vitro that the dual-
release of the peptide and the drug had a synergistic effect
regarding GLP-1 permeability. In the presence of the iDPP4,
the activity of the enzyme responsible for degrading GLP-1,
thus considerably decreasing its bioavailability, was drastically
reduced, further improving the amount of active peptide per-
meated in vitro across the intestinal cell monolayers.8
Additionally, using the microfluidics system, the functiona-
lized nanoparticles were encapsulated within an enteric
polymer – hydroxypropylmethylcellulose acetylsuccinate
(HPMC-AS) – conferring pH-sensitivity to the system and thus
enabling the release of nanoparticles only under the simulated
intestinal conditions.19,20 This synergetic effect was also
described for other carriers.21,22 Both PLGA and HPMC-AS
polymers are approved by the Food and Drug Administration
(FDA) for parenteral and food administration, respectively. Pre-
vious studies also show that they are extensively used in the
drug delivery field without toxic effects after acute and chronic
administrations.8,13,23,24
Pursuing these promising results, in the present work the
developed system was orally delivered to T2DM rat model,
induced by the combination of streptozotocin (STZ) and nicotin-
amide drugs. Blood glucose, plasmatic insulin levels, and insulin
pancreatic content were quantified over time during this study.
Experimental
Materials
GLP-1 acetate (7–37, MW 3355.7 Da) was purchased from
United Peptides (USA). iDPP4 (NVP DPP 728 dihydrochloride,
MW 375.77 Da) was purchased from Tocris Bioscience (UK)
and CPP R9 was purchased from GenicBio (China). PLGA
50 : 50 was obtained from Corbion Purac, Purasorb® PDLG
5004A, The Netherlands. Polyvinyl alcohol (PVA), medium
molecular weight CS, 2-(N-morpholino)-ethanesulfonic acid
(MES), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC),
N-hydroxysuccinimide (NHS), STZ, nicotinamide and iso-
flurane were purchased from Sigma-Aldrich (USA). HPMC-AS
was obtained from Shin-Etsu (Japan). Pluronic® F127 was pur-
chased from BASF (Germany). Lancet Unistik 2 Normal Fixed
Depth Lancet Needle 2.4 mm 21 Gauge was purchased from
Owen Mumford, Ltd (France) and FreeStyle Precision Blood
Glucose Test Strips from Abbott Diabetes Care (Portugal).
Preparation of GLP-1 loaded PLGA–CS nanoparticles
PLGA nanoparticles were produced based on the water-in-oil-
in-water (w/o/w) double emulsion technique, through the
modified solvent emulsification–evaporation method, using
2% of PVA as a surfactant, as described elsewhere.8,25 After-
wards, in order to functionalize the nanoparticles with CS, the
formulation was added into a CS solution at a ratio of 1 : 2
(w/w), regarding the solid content of the solutions, and left
overnight under magnetic stirring.8
CPP conjugation to the CS-functionalized nanoparticles
EDC/NHS coupling chemistry was used to covalently conjugate
the free amine groups in the CS structure with the carboxylic
group of CPP, as previously described.8 Briefly, the CS-functio-
nalized nanoparticles were dispersed in MES solution contain-
ing EDC and NHS (pH 5.5.). CPP was then added to this
dispersion in a ratio of 1 : 10 (CPP : nanoparticles, w/w) and
the conjugation occurred overnight in the dark under 300 rpm
stirring, forming PLGA + CS–CPP.
Characterization of nanoparticles
The nanoparticles were characterized with respect to their
average size (Z-average), polydispersity (PdI) and surface
charge zeta ((ζ)-potential) by dynamic light scattering using a
Malvern Zetasizer Nano ZS instrument (Malvern Instruments
Ltd, UK).
The association efficiency (AE) and loading degree (LD) of
GLP-1 were calculated by the difference between the total
amount of GLP-1 used to prepare the nanoparticles and the
amount of GLP-1 that remained in the aqueous phase after the
nanoparticle isolation by centrifugation at 20 000g for 30 min
at 4 °C. The amount of GLP-1 was determined by high
performance liquid chromatography (HPLC), as described
elsewhere.8
Microfluidics enteric encapsulation of nanoparticles
The GLP-1 loaded nanoparticles were encapsulated within the
HPMC-AS pH-sensitive polymer, loaded with the iDPP4, using
a double emulsion technique through a microfluidic flow-
focusing glass device. The preparation of the co-drug loaded
multifunctional systems was previously described in detail.8
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The modified nanoparticles encapsulated in the HPMC-AS
polymer are defined as H-PLGA particles.
The shape, size, morphology and surface topography of the
enteric encapsulated particles were assessed by scanning elec-
tron microscopy (SEM, Zeiss DSM 962, Germany). The AE of
the iDPP4 was calculated by dissolving the enteric encapsu-
lated particles in a pH 7.4 solution. The amount of iDPP4 was
determined by HPLC, as described elsewhere.8
Type 2 diabetic animals
Male Wistar rats, 7-weeks old, weighing 150–200 grams,
obtained from Harlan Laboratories, Inc. (Spain) were used for
the study. They were maintained under standard laboratory
conditions (12 h light/dark cycles, temperature of 21 ± 2 °C
and relative humidity of 35% to 60%). They were fed with
standard pellets and water ad libitum.
The rats were randomly divided into 6 groups, with 5
animals per group. The groups were named according to the
different formulations that were given as oral gavage: group
1 – normal animals (control group of normal rats and with no
T2DM induction); group 2 – phthalate buffer solution at
pH 4.0 (control group); group 3 – GLP-1 and iDPP4 aqueous
solution; group 4 – H-PLGA empty particles; group 5 – H-PLGA
particles loaded with GLP-1 (H-PLGA-GLP-1); and group
6 – H-PLGA particles loaded with GLP-1 and iDPP4
(H-PLGA-GLP-1-iDPP4) (study group). The amount of adminis-
tered particles was equivalent to a GLP-1 content of 200 µg per
kg of weight of the rat. This dose was chosen taking into
account the administration doses of the GLP-1 analogs that are
in the market [liraglutide (Victoza®) and exenatide (Byetta®)],
which is around 20–30 µg kg−1 and a previous study performed
by Huotari and co-workers where 50 µg of GLP-1 was s.c. admin-
istrated per mouse.26
Animal experiments were approved by the Local Ethics
Committee at the University of Porto and conducted under the
guidelines and recommendations of FELASA and the European
Directive 2010/63/EU.
Induction of T2DM in animals, with the exception of group
1, was done in overnight-fasted rats, by an intraperitoneal (i.p.)
injection of 120 mg per kg of nicotinamide and, 15 min later,
60 mg per kg of STZ. STZ was freshly dissolved in citrate buffer
(0.1 M; pH, 4.5) and nicotinamide was dissolved in normal
physiological saline buffer (pH 7.4), maintained on ice prior to
use.27
Glucose tolerance was determined by the intraperitoneal
glucose tolerance test (IPGTT) 3 days after the T2DM induc-
tion. Overnight-fasted animals were administered i.p. with a
glucose solution (2 g kg−1). Blood samples were taken by punc-
turing with the help of a lancet from the tail tip at different
time points (−15, 30, 60, 90, and 120 min) after glucose
administration. Blood glucose was measured using a gluco-
meter Precision Xtra (Abbott Diabetes Care, Portugal) by
placing a small drop of blood on a new test strip and recording
the measurements.
Hypoglycemic effect in vivo
After proving the successful T2DM induction through the
IPGTT experiments, different formulations were orally admini-
strated in a phthalate buffer (pH 4.0), according to the groups
defined in the previous section and blood glucose and insulin
levels in plasma and pancreas were measured.
Blood glucose measurements. The blood samples were with-
drawn from the tail vein and blood glucose levels were
measured for 8 h at different time points (0, 0.5, 1, 2, 4, 6 and
8 h) after administration. The area under the curve (AUC) over
8 h was calculated for each group. The total hypoglycemic
decrease (HD%) in serum glucose levels was calculated as
follows.3,28
AUC ðcontrol 0 480minÞ  AUC ðgroup 0 480minÞ
AUC ðcontrol 0 480minÞ  100
ð1Þ
Plasmatic insulin measurements. At the time points of 0, 2
and 6 h after administration, the withdrawn blood was col-
lected into Eppendorf tubes containing 0.5 M of EDTA (10% of
the final volume) to prevent blood clotting. The samples were
centrifuged at 5400g for 10 min at 4 °C. The supernatants were
collected and stored at −20 °C until further studies. Insulin
quantification was done according to the manufacturer’s
instructions using a rat insulin ELISA kit from Mercodia
(Sweden).
Pancreatic insulin content determination. At the end of the
study, the animals were sacrificed by cervical dislocation, after
isoflurane anesthesia, and the pancreases were extracted. The
pancreases were isolated by removing the fat and the connec-
tive tissues, and were weighed. Then, they were placed separ-
ately in 3 mL of ice cold acid ethanol (0.18 M HCl in 70%
ethanol) and kept on ice. The pancreases were further hom-
ogenized with a probe sonicator and 3 mL more of acid
ethanol were added into the tube of the tissue homogenate
and stored overnight at 4 °C. Afterwards, the samples were cen-
trifuged at 3500 rpm for 45 min at 4 °C and the supernatant
was transferred to another tube to be stored at −20 °C. These
steps were repeated twice more and the supernatants from
the different centrifugations were collected together. Before
the quantification of the insulin content, using the rat
insulin ELISA kit from Mercodia (Sweden), samples were left at
room temperature, mixed by vortexing, and diluted 1000–1500
times.
Statistical analysis
All the experiments were performed in triplicate and rep-
resented as mean ± standard deviation (SD). A Student t-test
and one-way analysis of variance (ANOVA) with unpaired and
Bonferroni post-test (GraphPadPrism, GraphPad software Inc.,
CA, USA) were used to analyze the data, respectively. The level
of significance was set at probabilities of *p < 0.05, **p < 0.01,
and ***p < 0.001.
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As previously demonstrated by our group, CS is able to
increase the permeability of the antidiabetic peptide GLP-1
across the intestinal cells.25,29 Due to its positive surface
charge, CS conferred a positive charge to the nanoparticles,
which increases the interaction with the negatively charged
intestinal cells and mucus layer. Additionally, CPP was also
conjugated to the CS-functionalized PLGA nanoparticles,
further enhancing the intestinal permeability of the GLP-1-
loaded CS-modified nanoparticles.8,14,30,31
After production and CS + CPP surface functionalization,
the PLGA nanoparticles were characterized on the basis of the
different physicochemical parameters that are known to have
an impact on their interaction with cells and on the drug deli-
very.32 The mean size, PdI, surface charge (ζ-potential), AE and
LD of GLP-1 were evaluated, as shown in Fig. 1. Comparing the
non-modified nanoparticles with the CS + CPP conjugated
nanoparticles, an increase in size from 174 ± 5 to 351 ± 4 nm,
an increase in PdI and an inverse of charge from −20 ± 2 to
40 ± 0 mV was observed, proving efficient modification of
the prepared PLGA nanoparticles.8,25 Due to the addition of
CS + CPP to the system, the final mass was increased resulting
in the decrease of the LD from 0.017 ± 0.03 to 0.08 ± 0.01.
However, despite these surface modifications, the AE did not
significantly change (approximately 70%) (Table 1).
Further encapsulation of the CS + CPP modified nano-
particles with a pH-sensitive HPMC-AS polymer was made
using the droplet microfluidics technique,19,20 to form H-PLGA
particles. These particles presented sizes around 60 ± 7 µm
with a regular and smooth surface and a spherical shape
(Fig. 1). The similarities between the particles are character-
istic of the microfluidic production technique, which orig-
inates uniform structures, with the additional advantage
of providing an AE of nearly 100%.8,19,20 The AE of iDPP4 was
21 ± 4%. Since HPMC-AS is only soluble at pH 6.0 or higher,
under low pH conditions of the gastric milieu, the particles
will remain intact protecting the integrity of the CS + CPP
modified nanoparticles.8,20
In vivo assessment of the antidiabetic effect
A non-obese T2DM rat model induced by the administration of
STZ combined with nicotinamide, was firstly proposed by
Masiello and co-workers in 1998.27 This model was described
as being the most suitable to study the biochemical and
pharmacological antidiabetic drug effects, and was previously
used to test GLP-1 analogs.16,33,34 It is based on the protective
effects of nicotinamide against the β-cytotoxic effects caused
by STZ, a widely used drug to induce diabetes mellitus in
rodents.35 This model presents a number of features similar to
T2DM, as described in detail elsewhere.34
Briefly, it induces stable and moderate hyperglycemia,
does not require exogenous insulin for animals to survive,
results in glucose intolerance, reduction of β cells and the
presence (although impaired) of glucose-stimulated insulin
secretion.36
After 3 days of STZ–nicotinamide administration, a glucose
tolerance test (IPGTT) was performed to verify the efficacy of
the induction of T2DM.34 The glucose tolerance test was used
to assess the ability of the body to metabolize glucose, and
thus, to detect disorders in glucose metabolism. After the i.p.
administration of glucose, the blood glucose levels were
measured for 2 h in the different groups. As shown in Fig. 2A,
the normal animals’ group had a rapid increase in the blood
glucose levels 30 min after glucose administration, but the
levels reached normal values 60 min after glucose adminis-
tration and were constant, thereafter, i.e., the animals were
tolerant to glucose.37 In contrast, the other groups could not
recover from the glucose administration. There was a
maximum peak between 30 and 60 min, similar to the normal
animals, but the blood glucose levels never reached the
normal values in the 2 h period after glucose injection. As
shown in Fig. 2B, all the groups presented a higher and stat-
istically significant AUC compared to the normal animals’
group, in the period of −15–120 min of the study, which indi-
cates that all the animals were intolerant to glucose, and thus,
were considered as presenting T2DM.37
To evaluate the efficacy of our developed composite
system, different formulations were orally administrated to
the animals through gavage, as previously described in the
Experimental section. The drug-loaded H-PLGA particles
(H-PLGA-GLP-1-iDPP4) showed remarkable hypoglycemic
effects (decrease in the blood glucose levels) in a sustained
Fig. 1 SEM image of CS-CPP modified nanoparticles encapsulated in
the HPMC-AS polymer (H-PLGA particles).
Table 1 Characterization of the nanoparticles with respect to their
size, PdI, ζ-potential, AE and LD of GLP-1. Results are presented as mean
± SD (n ≥ 3)
PLGA PLGA + CS PLGA + CS + CPP
Size (nm) 174.4 ± 4.9 286.7 ± 5.5 351.3 ± 3.5
PdI 0.120 ± 0.045 0.188 ± 0.015 0.210 ± 0.024
ζ-potential (mV) −20.0 ± 1.5 34.7 ± 2.8 40.0 ± 0.1
AE (%) 69.5 ± 10.3 ∼69.5 ± 10.3 ∼69.5 ± 10.3
LD (%) 0.017 ± 0.030 0.008 ± 0.001 0.008 ± 0.001
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and prolonged manner. 2 h after administration, the blood
glucose levels decreased significantly, remaining low until the
end of the experiment (8 h). In comparison with other groups,
at 4, 6 (p < 0.05) and 8 h (p < 0.001) after administration,
results with H-PLGA-GLP-1-iDDP4 particles were statistically
different (Fig. 3A). The determination of glucose AUC of the
whole experiment (0–480 min), shown in Fig. 3B, proved that
the GLP-1 and iDPP4 co-loaded particles had a statistically
significant effect in decreasing the overall glucose levels
compared to the control and the pure drugs, as well as in com-
parison with the empty H-PLGA and H-PLGA-GLP-1 particles
(p < 0.01). The hypoglycemic decrease (HD%) presented in
Table 2 also gives consistency to the obtained results, showing
a HD% of approximately 0 for the GLP-1-iDPP solution and
H-PLGA-GLP-1, 4.3 ± 6.4% for the empty H-PLGA particles,
which is a negligible hypoglycemic efficacy,28 and 44.3 ± 4.0%
for the DPP4-loaded H-PLGA particles. This hypoglycemic
efficacy was similar28 or even higher38,39 than the results
obtained in other studies where GLP-1 analogs were tested.
Since the analogs are resistant to the DPP4 enzyme activity, we
can assume that the dual delivery of GLP-1 and iDPP4 was
effective, and that they had a synergetic effect regarding the
blood glucose levels, as previously described for the in vitro
experiments.8,24 Moreover, the functionalization of the PLGA
nanoparticles improved the permeability of cells to GLP-1 and
contributed to the overall increase in efficacy.8,25
Being a powerful insulinotropic peptide, GLP-1 stimulates
pancreatic insulin secretion and release in a glucose-depen-
dent manner. Even in a T2DM scenario, the insulin response
to GLP-1 remains intact,40 which means that after adminis-
tration of GLP-1 in therapeutic dosages, the insulin secretory
function can be restored in T2DM patients.41 This glucose
dependency assures the safety of GLP-1 over other agents in
Fig. 2 Blood glucose levels of T2DM-induced rats following i.p. admin-
istration of a glucose solution (2 g kg−1). The values were normalized by
the normal animals’ group. Results are presented as mean ± SD (n = 5)
(A). Blood glucose AUC in the period of −15–120 min after glucose
administration. Results are presented as mean ± SD (n = 5). The levels of
significance were set at probabilities of **p < 0.01, and ***p < 0.001, as
compared with the normal animals’ group (B).
Fig. 3 Blood glucose levels of T2DM-induced rats following oral
administration of phthalate buffer solution (control), GLP-1-iDPP4 solu-
tion, H-PLGA particles, H-PLGA-GLP-1 particles and H-PLGA-GLP-1-
iDPP4 particles. Results are presented as mean ± SD (n = 5) (A). Blood
glucose AUC in the period of 0–480 min after oral administration.
Results are presented as mean ± SD (n = 5). The levels of significance
were set at the probability of ***p < 0.001, as compared with the
H-PLGA-GLP-1-iDPP4 (B).
Table 2 Total hypoglycemic decrease (HD%) in serum glucose levels in





∼0 4.3 ± 3.6 ∼0 44.3 ± 2.9
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the market that increase insulin secretion via glucose-indepen-
dent mechanisms.38,39
Thus, the plasmatic insulin levels were also measured for
the time points of 0, 2 and 6 h after oral administration. As is
depicted in Fig. 4A, no differences between the groups were
found for the initial time points (0 and 2 h). However, at 6 h
after oral administration, the H-PLGA-GLP-1-iDPP4
particles presented significantly higher plasmatic insulin
levels compared to the control, the oral GLP-1-iDPP4 solution,
the H-PLGA empty particles and the H-PLGA-GLP-1 groups
(p < 0.001).
These results are in accordance with the blood glucose level
measurements where the blood glucose levels were lower at
the time point of 6 h (p < 0.05) in comparison with the 0 and
2 h time points. This is also in agreement with another study
that showed an insulin increase in a slow, but prolonged
manner over 8 h.39
The insulin pancreatic contents of the different groups
after oral administration were also evaluated at the end of the
8 h experiment, as shown in Fig. 4B. The H-PLGA-GLP-1-
iDPP4 group presented a higher amount of insulin compared
with the other groups; however, this difference was only stat-
istically significant with regard to the control group. These
results might be due to the single dose administration, while
an increase in the insulin pancreatic content was reported to
exist only in long-term studies.42–46 Thus, although promising,
these results must be followed up by a chronic diabetic model
system.
Overall, the combined administration of GLP-1 and iDPP4
resulted in an increase in the hypoglycemic effects after oral
administration, namely a decrease of blood glucose levels and
enhancement of the insulin secretion. A clear improvement of
the therapeutic efficacy of GLP-1 was observed in the presence
of the iDPP4.47–49
Conclusions
In this work, a dual-drug delivery multifunctional composite
system was prepared through the highly reproducible micro-
fluidics technique. The system was loaded with GLP-1 and
iDPP-4 and tested in vivo in a non-obese type 2 diabetes melli-
tus rat model, induced by streptozotocin and nicotinamide.
The combination of both GLP-1 and iDPP-4 resulted in an
increase in the hypoglycemic effects in a sustained and pro-
longed manner. The glucose AUC was significantly lower than
the control group, with a hypoglycemic decrease of 44%. An
enhancement of the plasmatic insulin levels was also observed
6 h after the oral administration of the system. These are very
promising results towards the development of oral protein/
peptide delivery systems for T2DM therapy.
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